subject: Global Data: Acute Myeloid Leukemia (AML) - Pipeline Assessment and Market Forecasts [print this page] Global Data: Acute Myeloid Leukemia (AML) - Pipeline Assessment and Market Forecasts
GlobalData has released its pharmaceutical report, "Acute Myeloid Leukemia (AML) - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global AML therapeutics market. The report identifies the key trends shaping and driving the global AML therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global AML therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. GlobalData estimated the global AML therapeutics market to be worth $174m in 2009. It is expected to grow to $279m with a Compound Annual Growth Rate (CAGR) of 6.1% by 2017. This growth is primarily attributed to the increase in the prevalence of the disease due to the increasing elderly population and the presence of a strong pipeline with many emerging therapies. Pfizer and Genzyme remain the market leaders within the global AML therapeutics market. There is a high level of unmet need in the current AML therapeutics market in terms of both safety and efficacy.
* The report provides information on the key drivers and challenges of the AML market. Its scope includes:
* Annualized global AML market revenues data from 2001 to 2009, forecast for eight years to 2017.
* Pipeline analysis data provides a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as of DNA synthesis inhibitors, HDAC inhibitors, DNA methyltransferase inhibitors and Aurora kinase inhibitors, CD33 antigen targeters, Farnesyl transferase inhibitors and Topoisomerase II inhibitors.
* Analysis of the current and future competition in the global AML market. The key market players covered are Pfizer, Genzyme, Topo Target A/S, and Vion Pharmaceuticals.
* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
* Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the AML therapeutics market.
GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.
Visit our Report Store
http://www.globaldata.com/reportstore/
welcome to Insurances.net (https://www.insurances.net)
